No, I haven't taken it but after reading all of the links in this thread, I find it pretty intriguing myself. It's supposed to be abundant in plant sources so if you don't want to pop another pill, maybe that's a more natural way to boost your PQQ. I wonder if something doesn't interfere with it's absorption...
I'm about to cross a topic line again....it could be helpful to minimize reperfusion/CCSVI damage too. A multi-tasker! There is a lot more info at that wiki link.
PQQ protects brain cells against oxidative damage following ischemia-reperfusion injury—the inflammation and oxidative damage that result from the sudden return of blood and nutrients to tissues deprived of them by stroke.[40
The study cited ...
The putative essential nutrient pyrroloquinoline quinone is neuroprotective in a rodent model of hypoxic/ischemic brain injury
F.E. Jensen, *, G.J. Gardner*, A.P. Williams*, P.M. Gallop§, E. Aizenman∥, P.A. Rosenberg*
* Department of Neurology , Enders 260, Children's Hospital, 300 Longwood Avenue and Harvard Medical School, Boston, MA 02115, U.S.A.
§ Laboratory of Human BiochemistryEnders 260, Children's Hospital, 300 Longwood Avenue and Harvard Medical School, Boston, MA 02115, U.S.A.
∥ Department of Neurobiology, University of Pittsburgh School of Medicine, PA 15261, U.S.A.http://dx.doi.org/10.1016/0306-4522(94
)90375-1, How to Cite or Link Using DOI
Pyrroloquinoline quinone is a ubiquitous redox cofactor and putative essential nutrient in mammals. Pyrroloquinoline quinone has recently been demonstrated to depress N-methyl-d-rasparate induced electrical responses and is neuroprotective in vitro. In addition, pyrroloquinoline quinone has been demonstrated to act as a free radical scavenger in mammalian tissues. In this study, we demonstrate a neuroprotective effect of pyrroloquinoline quinone in an in vivo cerebral hypoxia/ischemia model in the rodent. Significant reduction in infarct size resulted from pyrroloquinoline quinone pretreatment and also when pyrroloquinoline quinone was administered following induction of hypoxia/ischemia. The neuroprotective effect was not dependent on change in core or cranial temperatures, as there was no difference between temperature measurements in pyrroloquinoline quinone-treated and vehicle-treated controls. No changes in electroencephalographie activity were observed at neuroprotective doses. These findings suggest that pyrroloquinoline quinone may represent a novel class of quinoid reagents of potential use in the treatment of neurological disorders that involve excitotoxicity.
This study demonstrates a protective effect of the novel essential nutrient pyrroloquinoline quinone on brain injury in a rodent model of cerebral hypoxia/ischemia. Pyrroloquinoline quinone was neuroprotective when administered before and even after the insult, and did not appear to have significant neurobehavioral side effects. Pyrroloquinoline quinone represents a new class of agents with potential use in the therapy of stroke.